B
Bull
Bull · 25%RAPT
$11.65
Scenario price
$58.020
+0.041 (+0.07%)At close
Loading chart…
- High
- 58.020
- Open
- 57.980
- VWAP
- 58.01
- Vol
- 11.13M
- Mkt Cap
- 100.87M
- Low
- 57.980
- Amount
- 645.34M
- EV/EBITDA, TTM
- -6.74
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
AI analysis of RAPT Therapeutics Inc (RAPT)
holdRAPT Therapeutics is not a good buy for a beginner, long-term investor at this time. The stock is trading near its acquisition price of $58 per share, and the upside potential is minimal due to the finalized acquisition agreement with GSK. Analysts have downgraded the stock to neutral or hold ratings, and there are no significant catalysts or growth opportunities in the near term.
Valuation Metrics
The current forward P/E ratio for RAPT Therapeutics Inc (RAPT) is -10.65, compared to its 5-year average forward P/E of -5.73.
Alphio AI Price Scenarios for RAPT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding RAPT
Events Timeline
News
8.503-22FoolFCPM III Services B.V. Acquires 1.49 Million Shares of RAPT Therapeutics
8.503-15FoolOrbiMed Advisors Acquires Additional Shares of RAPT Therapeutics
8.503-03Yahoo FinanceGSK Completes Acquisition of RAPT Therapeutics
8.502-25FoolGreat Point Partners Acquires Stake in RAPT Therapeutics
8.502-25BenzingaGSK Acquires 35Pharma for $950 Million
RAPT FAQ — answered by Alphio AI
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
RAPT Therapeutics is not a good buy for a beginner, long-term investor at this time. The stock is trading near its acquisition price of $58 per share, and the upside potential is minimal due to the finalized acquisition agreement with GSK. Analysts have downgraded the stock to neutral or hold ratings, and there are no significant catalysts or growth opportunities in the near term.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.